Table 1. Baseline characteristics of patients (n = 93).
| Characteristics | Values | |
|---|---|---|
| Male sex | 59 (63.4) | |
| Diagnosis | ||
| CD | 78 (83.9) | |
| UC | 15 (16.1) | |
| Age at diagnosis, yr | 13.8 ± 2.8 | |
| Age at interview, yr | 18.6 ± 3.7 | |
| < 20 | 59 (63.4) | |
| ≥ 20 | 34 (36.6) | |
| Duration of follow-up, yr | 4.81 ± 3.4 | |
| Medical history | ||
| 5-aminosalicylic acid, sulfasalazine or mesalamine | 93 (100) | |
| Steroid | 89 (95.7) | |
| Immunomodulator, azathioprine or methotrexate | 68 (73.1) | |
| Biologic, infliximab or adalimumab | 55 (59.1) | |
| No. of hospitalizations | 2.5 ± 1.7 | |
| No. of hospitalizations/yr (n = 87)a | 0.8 ± 0.9 | |
| No. of endoscopic examinationsb | 4.3 ± 1.5 | |
| No. of endoscopic examinations/yr (n = 87)a | 1.3 ± 1.1 | |
| No. of patients who underwent surgery | 36 (38.7) | |
Values are presented as number (%) or mean ± standard deviation.
CD = Crohn's disease, UC = ulcerative colitis.
aSix patients with a follow-up of less than 6 months were excluded; bEndoscopic examinations include duodenofibroscopy, capsule endoscopy, and colonoscopy.